barrons.com
Mpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look.
The first severe case of the virus has been detected in New York.
Novavax, Inc.NVAXNASDAQ
Loading
Latest News
zacks.com
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
seekingalpha.com
Novavax, Inc. (NVAX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Novavax, Inc. (NVAX) Presents at Leerink Global Healthcare Conference 2026 Transcript
seekingalpha.com
Novavax, Inc. (NVAX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Novavax, Inc. (NVAX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
zacks.com
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
benzinga.com
What's Going On With Novavax Stock On Friday?
Novavax Inc. (NASDAQ: NVAX) shares are down on Friday, possibly on profit-taking after the stock rallied on Thursday following the company's announcement of its fourth-quarter and full-year 2025 financial results.
seekingalpha.com
Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof
Novavax (NVAX) has transitioned into a royalty-driven model, with Q4 profitability and 73% of revenue from licensing and royalties. NVAX's FY26 revenue guidance of $230M–$270M reflects cleaner, high-margin cash flow, excluding potential $200M in milestones from Sanofi. With $857M in cash and receivables, NVAX is funded into 2028, but remains highly dependent on partner outcomes, especially Sanofi's COVID/influenza program.
zacks.com
Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates
NVAX stock jumps 17% after Q4 swings to a surprise profit on strong licensing revenues and lower costs, with sales soaring 67% year over year.
prnewswire.com
Novavax to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., Feb. 26, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that it will participate in the following upcoming investor conferences: TD Cowen 46 th Annual Health Care Conference: Fireside Chat Date: Tuesday, March 3, 2026 Time: 2:30 p.m.
seekingalpha.com
Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript
Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript
benzinga.com
COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb
Novavax Inc. (NASDAQ: NVAX) shares are up on Thursday following the company's announcement of its fourth-quarter and full-year 2025 financial results.
zacks.com
Novavax (NVAX) Beats Q4 Earnings and Revenue Estimates
Novavax (NVAX) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.66 per share. This compares to a loss of $0.51 per share a year ago.
schaeffersresearch.com
S&P 500, Nasdaq Struggle Amid AI Rotation Pain
While the Dow is higher, the Nasdaq and S&P 500 are struggling for gains as AI sentiment dampens
reuters.com
Novavax raises 2026 adjusted revenue outlook on strength in vaccine deals
Novavax raised its adjusted revenue forecast for 2026 on Thursday, as it expects milestone payments from vaccine supply and licensing deals to offset pressure from sagging demand.
prnewswire.com
Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas Multiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025 Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for the full year 2025 Continued advancement of early-stage pipeline with the intention to enter the clinic as early as 2027 Year end 2025 Cash of $751 million Novavax exceeded its full year 2025 R&D and SG&A expense reduction goals and is improving future targets GAITHERSBURG, Md., Feb. 26, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and year ended December 31, 2025.
zacks.com
Novavax (NVAX) Upgraded to Buy: Here's What You Should Know
Novavax (NVAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
What's in Store for These 5 Medical Companies This Earnings Season?
IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.
defenseworld.net
Jupiter Asset Management Ltd. Sells 779,802 Shares of Novavax, Inc. $NVAX
Jupiter Asset Management Ltd. trimmed its position in Novavax, Inc. (NASDAQ: NVAX) by 88.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 100,608 shares of the biopharmaceutical company's stock after selling 779,802 shares during the quarter. Jupiter Asset Management Ltd. owned
prnewswire.com
Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m.
zacks.com
Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.